Safety profile of nivolumab administered as 30-min infusion: analysis of data from CheckMate 153

Nivolumab has been administered using a 60-min infusion time. Reducing this time to 30 min would benefit both patients and infusion facilities. This analysis compared the safety of 30- and 60-min infusions of nivolumab in patients with previously treated advanced non-small cell lung cancer. CheckMate 153 is an open-label, phase 3b/4, predominantly community… (More)